Study
| Open-label, phase 2 study [NCT01130519] |
| Advanced HLRCC-associated or sporadic papillary renal-cell carcinoma |
| Bevacizumab (10 mg/kg every 2 wks) + Erlotinib (150 mg daily) |
Efficacy
| ORR: 72% [57 – 83] vs 35% [22 – 51] |
| CR: 5% vs 0% |
| mPFS: 21.1 mos [15.6 – 26.6] vs 8.9 mos [5.5 – 18.3] |
| mOS: 44.6 mos [32.7 – NE] vs 18.2 mos [12.6 – 29.3] |
Safety
| Grade >=3 AE: Hypertension (34%), Proteinuria (17%) |
| Serious AEs: Acute coronary syndrome, Bronchopulmonary hemorrhage |
| Treatment discontinuations: Bevacizumab (4%), Erlotinib (1%) |
N Engl J Med 2025;392:2346
http://doi.org/10.1056/nejmoa2200900
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
